Mr. Thomas Smeenk reports

HEMOSTEMIX SUBMITS ITS RETROSPECTIVE HEART STUDY TO LEADING STEM CELL JOURNAL AND HAS PREPARED ITS CLI PHASE II CLINICAL TRIAL MANUSCRIPT FOR PEER REVIEW

Hemostemix Inc. has submitted for publication its retrospective cardiomyopathy study to a leading stem cell journal. The study, Safety and Outcomes Analysis: Transcatheter Implantation of Autologous Angiogenic Cell Precursors for Treatment of Cardiomyopathy, was co-authored by Jane R. Schubart PhD, Amirhossein Zare MD, Roberto M. Fernandez-de-Castro MD, MSc, Hector Rosario Figueroa MD, Ina Sarel PhD, Kelly Tuchman RN, Kaitlyn Esposito MPH, Fraser C. Henderson Sr MD, Ernst von Schwarz MD, PhD.

Hemostemix is also pleased to announce it has prepared its CLI phase II clinical trial manuscript for publication and peer review. The CLI manuscript, REPORT FROM A PHASE 2 PROSPECTIVE RANDOMIZED PLACEBO CONTROLLED TRIAL OF AUTOLOGOUS STEM CELLS TO TREAT PATIENTS WITH NO OPTION CRITICAL LIMB ISCHEMIA: THE ACP-CLI TRIAL is co-authored by Ishmam Bhuiyan MD Student, Sally Choi MD, Jon Misskey MD, MHSE,, Ina Sarel PhD, Fraser Henderson, Sr MD, Yi Wang PhD, Kelly Tuchman RN, Mary Argent-Katwala PhD, Thomas Smeenk BA, York Hsiang MB, ChB, MHSc.

"I am pleased to have both the ACP-01 retrospective cardiomyopathy study and the phase II CLI clinical trial submitted and ready for peer review, respectively," stated Thomas Smeenk, CEO. "I want to thank the co-authors for their significant contributions. Once accepted, we will make a further announcement. We are continuing with the study of the remaining historical ACP-01 recipients' medical charts, as this may generate one more peer reviewed paper," Smeenk said.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO & Co-FounderEM: tsmeenk@hemostemix.com PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

We seek Safe Harbor.